Barclays PLC Has $3.61 Million Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Barclays PLC raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 9.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 142,914 shares of the biopharmaceutical company's stock after buying an additional 12,533 shares during the quarter. Barclays PLC owned about 0.22% of Celldex Therapeutics worth $3,611,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. American Century Companies Inc. increased its stake in Celldex Therapeutics by 46.5% in the fourth quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company's stock valued at $15,376,000 after acquiring an additional 193,093 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Celldex Therapeutics in the 4th quarter valued at $3,452,000. Sovran Advisors LLC bought a new position in shares of Celldex Therapeutics in the 4th quarter valued at $2,867,000. Fisher Asset Management LLC raised its holdings in shares of Celldex Therapeutics by 20.9% during the 4th quarter. Fisher Asset Management LLC now owns 452,497 shares of the biopharmaceutical company's stock worth $11,435,000 after buying an additional 78,145 shares in the last quarter. Finally, Cinctive Capital Management LP lifted its position in shares of Celldex Therapeutics by 140.6% during the 4th quarter. Cinctive Capital Management LP now owns 81,320 shares of the biopharmaceutical company's stock worth $2,055,000 after buying an additional 47,523 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages have commented on CLDX. UBS Group started coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They set a "buy" rating and a $44.00 target price for the company. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research report on Friday, February 28th. Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They issued a "buy" rating and a $64.00 target price on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Finally, Morgan Stanley started coverage on Celldex Therapeutics in a report on Thursday, March 20th. They set an "overweight" rating and a $46.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $55.30.

Celldex Therapeutics Stock Down 0.2 %

Shares of NASDAQ CLDX traded down $0.05 during trading on Friday, reaching $20.66. The company had a trading volume of 598,699 shares, compared to its average volume of 884,988. The stock has a market cap of $1.37 billion, a P/E ratio of -8.04 and a beta of 1.59. The company's fifty day moving average price is $19.09 and its 200-day moving average price is $23.17. Celldex Therapeutics, Inc. has a 12 month low of $14.40 and a 12 month high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The business had revenue of $1.18 million for the quarter, compared to analysts' expectations of $1.25 million. As a group, equities analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.